Mizuho Starts Coverage on Tarsus Pharmaceuticals With Bullish $100 Target
Mizuho initiates coverage on Tarsus Pharmaceuticals with an Outperform rating and a $100 price target, citing strong prospects for Xdemvy and projected peak sales above $2B.
/ 913 items
#Healthcare↓
Cantor Fitzgerald Starts Coverage on Lexeo Therapeutics with Strong Outlook
Cantor Fitzgerald initiates coverage of Lexeo Therapeutics with an Overweight rating, praising its cardiac gene therapy programs and transparent updates.
Nuvation Bio Soars on Ibtrozi Success and Analyst Upgrades
Nuvation Bio shares jump 49% Wed. after strong Ibtrozi results and analyst upgrades, signaling growth potential in biotech and cancer treatments.
Abbott Makes Major Move in Cancer Diagnostics with $21B Exact Sciences Acquisition
Abbott to acquire Exact Sciences for $21 billion, gaining leadership in cancer screening with Cologuard and expanding its diagnostics portfolio into fast-growing oncology segment.
RBC Upgrades Design Therapeutics on Strong 2026 Outlook
RBC Capital upgrades Design Therapeutics to Outperform with a new $13 price target, citing promising 2026 milestones, positive data potential, and long-term revenue upside.
FDA Approves Eylea HD for Retinal Vein Occlusion Treatment
Regeneron's Eylea HD receives FDA approval for treating macular edema from retinal vein occlusion with flexible dosing options, potentially reducing injection frequency.